(FAQ) - Highly Potent Active Pharmaceutical Ingredients

Highly potent APIs (HPAPIs) are among the most challenging compounds to manufacture due to their extremely low occupational exposure limits — often below 1 µg/m³ — and the need for rigorous containment to protect both personnel and product quality. These compounds are typically classified into Occupational Exposure Bands (OEB1–OEB5), with each level defining the containment strategies, facility requirements, and operational controls necessary for safe handling.

Successful HPAPI manufacturing depends on a combination of advanced engineering controls, robust quality systems, and deep scientific expertise. Effective risk assessments incorporate toxicology, structural analogs, thermal stability, and explosivity data to guide process and facility design. While PPE plays a supporting role, primary protection is achieved through engineered containment solutions such as closed transfer systems, pressure cascades, dedicated HVAC infrastructure, and isolator technologies. Single-use containment systems can further improve operational flexibility and reduce cleaning validation burdens.

Because cross-contamination control is critical, HPAPI operations rely on risk-based cleaning limits, highly sensitive analytical methods, and validated verification programs. Common HPAPIs include oncology compounds, hormones, steroids, and other highly active small molecules, making specialized CDMO partnerships essential for safe, compliant, and efficient development and manufacturing across the product lifecycle.